J. Safra Sarasin Holding AG Buys 5,986 Shares of Zimmer Biomet Holdings, Inc. $ZBH

J. Safra Sarasin Holding AG lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 93.1% in the third quarter, HoldingsChannel reports. The fund owned 12,415 shares of the medical equipment provider’s stock after acquiring an additional 5,986 shares during the period. J. Safra Sarasin Holding AG’s holdings in Zimmer Biomet were worth $1,223,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also bought and sold shares of ZBH. Cullen Frost Bankers Inc. boosted its stake in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares in the last quarter. Root Financial Partners LLC purchased a new stake in Zimmer Biomet during the third quarter valued at $31,000. Mather Group LLC. purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at about $36,000. Finally, Headlands Technologies LLC purchased a new stake in Zimmer Biomet during the second quarter valued at approximately $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a research note on Thursday, January 8th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, January 21st. Finally, Barclays decreased their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $107.24.

Zimmer Biomet Stock Down 0.4%

Zimmer Biomet stock opened at $85.67 on Thursday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.91 and a fifty-two week high of $114.44. The business’s 50-day simple moving average is $91.18 and its two-hundred day simple moving average is $96.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The company has a market cap of $16.98 billion, a PE ratio of 21.21, a PEG ratio of 2.19 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. Zimmer Biomet’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period last year, the firm posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.